Article

Perimeter's diagnostic capabilities allow for early detection of CNV

The Foresee PHP, a second-generation Preferential Hyperacuity Perimeter is available for improved detection and early diagnosis of the most aggressive and sight-threatening form of age-related macular degeneration (AMD). Developed by Notal Vision and distributed exclusively in the United States by MSS, the device represents a technologic leap for monitoring AMD and is a clinically validated diagnostic device for improved early detection of choroidal neovascularization (CNV).

The Foresee PHP, a second-generation Preferential Hyperacuity Perimeter, is available for improved detection and early diagnosis of the most aggressive and sight-threatening form of age-related macular degeneration (AMD). Developed by Notal Vision and distributed exclusively in the United States by MSS, the device represents a technologic leap for monitoring AMD and is a clinically validated diagnostic device for improved early detection of choroidal neovascularization (CNV).

The device is the follow-up to the Preview PHP and allows eye-care professionals to track any changes to a patient's visual field resulting from the advancement of AMD. The updated device is completely automated, allowing for patient self-operation, while still exhibiting high sensitivity and specificity. The Foresee PHP also has a larger normative database, provides faster testing and test analysis, and generates advanced reports that feature a map of the patient's visual field indicating the relative location of abnormalities in the macular area.

The Foresee PHP maps defects within a patient's visual field by analyzing responses to "dot deviation signals" flashing on a computer screen. The patient uses a stylus pen to touch the screen to identify the most prominent distortion in the line. The response patterns are recorded, analyzed and compared with the normative database, producing a report revealing the relative location of the defects in the macular area.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.